Graft-Vs-Host Disease

>

Latest News

Image of red blood cells
FDA Declines Breakthrough Status, Halts Itolizumab’s Path Forward in Acute GVHD

April 27th 2025

The FDA’s decision not to grant breakthrough designation or accelerated approval for itolizumab in acute GVHD has led to the discontinuation of the pivotal phase 3 EQUATOR trial.

Photo of a patient holding a prescription bottle of pills and speaking with a doctor holding a clipboard
Pacritinib Shows Preliminary ORR in Chronic Graft-Vs-Host Disease

April 9th 2025

dark blue background with a white outline indicating blood cells
MaaT013 Achieves Primary Endpoint in ARES Trial for GI-aGVHD

January 16th 2025

FDA Approves Axatilimab for Chronic Graft-vs-Host Disease
FDA Approves Axatilimab for Chronic Graft-vs-Host Disease

August 14th 2024

BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD
BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

August 11th 2024

Study Hall

Study Hall powered by, Oncology Nursing News is a dedicated hub designed for Advanced Practice Providers, offering an easy-to-navigate platform to support your clinical practice. Explore a comprehensive collection of articles, videos and learning modules.

Study Hall powered by, Oncology Nursing News is a dedicated hub designed for Advanced Practice Providers, offering an easy-to-navigate platform to support your clinical practice. Explore a comprehensive collection of articles, videos and learning modules.